Lung cancer is one of the most deadly cancers worldwide, with non-small cell lung cancer (NSCLC) being the most common form. While early-stage NSCLC can often be treated with surgery, up to 30-75% of patients experience recurrence after the procedure. Researchers have now developed a novel nomogram that can accurately predict the risk of early recurrence in patients with stage IB lung adenocarcinoma (LUAD), the most prevalent NSCLC subtype. The model is based on inflammation and nutrition markers that are easily measurable, making it a valuable tool for clinicians to guide post-operative treatment decisions.
Inflammation, Nutrition, and Lung Cancer Prognosis
Lung cancer prognosis is influenced not only by tumor-related factors, but also by the patient’s immune function, nutritional status, and inflammatory responses. Previous studies have shown that markers like ratio’>lymphocyte-to-monocyte ratio (LMR), and mutation’>EGFR mutations, to further refine the predictive model.
Overall, this study highlights the importance of considering both tumor-related and patient-related factors, such as inflammation and nutrition, when assessing the prognosis of early-stage lung cancer. The development of this nomogram represents a significant step towards personalized management of stage IB LUAD, potentially improving outcomes for these patients.
Author credit: This article is based on research by Xianneng He, Yishun Xiang, Chengbin Lin, Weiyu Shen.
For More Related Articles Click Here
</a> are associated with the prognosis of various cancers, including NSCLC.</p>
<p><h3>Developing a Predictive Nomogram for Stage IB LUAD</h3>
</p>
<p>In this study, the researchers analyzed data from 199 stage IB LUAD patients who underwent surgical resection. They identified several independent risk factors for early recurrence, including:</p>
<p>– <b>Vascular invasion</b>: Tumor invasion into blood or lymphatic vessels, indicating increased risk of metastasis.<br />
– <b>Pleural visceral invasion</b>: Invasion of the tumor into the visceral pleura, also associated with poorer prognosis.<br />
– <b>Predominant tumor pattern</b>: Micropapillary and solid subtypes were linked to higher recurrence risk.<br />
– <b>High preoperative NLR</b>: Elevated neutrophil-to-lymphocyte ratio, indicating systemic inflammation.<br />
– <b>High preoperative PLR</b>: Elevated platelet-to-lymphocyte ratio, another marker of inflammation.<br />
– <b>Low preoperative PNI</b>: Decreased prognostic nutritional index, reflecting poorer nutritional status.</p>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729767774_41598_2024_76230_Fig1_HTML.png" alt="" class="wp-image-1" /><figcaption class="wp-element-caption">Table 1 Comparision of clinicopathological characterisstics in training and validation cohorts.</figcaption></figure>
</p>
<p>The researchers then developed a <b>nomogram</b> incorporating these six independent risk factors to predict the 1-year, 2-year, and 3-year recurrence-free survival (RFS) rates for stage IB LUAD patients. The nomogram demonstrated excellent discriminative and calibration abilities, with high area under the curve (AUC) values in both the training and validation cohorts.</p>
<p><h3>Implications and Future Directions</h3>
</p>
<p>This inflammation-nutrition indices-based nomogram offers a valuable tool for clinicians to identify stage IB LUAD patients at high risk of early recurrence after surgical resection. By incorporating easily measurable biomarkers, the model can help guide personalized treatment decisions, such as the need for adjuvant chemotherapy or closer monitoring.</p>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729767776_41598_2024_76230_Fig2_HTML.png" alt="figure 1" class="wp-image-2" /><figcaption class="wp-element-caption">Fig. 1</figcaption></figure>
</p>
<p>Interestingly, the study found that postoperative adjuvant chemotherapy did not significantly improve outcomes for these patients, which the authors suggest may be due to the lack of data on targeted therapies. Future research should explore the incorporation of molecular markers, such as <a href=){kind=link}